Alterity Therapeutics Files 6-K, Incorporates Preliminary Report
Ticker: PRNAF · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, registration-statement, financial-report
TL;DR
Alterity Therapeutics filed a 6-K, linking its preliminary report to existing SEC filings.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on August 29, 2024, incorporating by reference its Appendix 4E Preliminary Final Report. This filing is also being incorporated into several of the company's existing registration statements on Forms S-8 and F-3.
Why It Matters
This filing serves to update SEC registration statements, indicating ongoing corporate actions and compliance for Alterity Therapeutics Ltd.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previously issued financial information into existing SEC registration statements.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- August 2024 (date) — Reporting period for Form 6-K
- Appendix 4E Preliminary Final Report (document) — Incorporated by reference
- Form S-8 (document) — Registration statement
- Form F-3 (document) — Registration statement
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is being filed to incorporate by reference the Appendix 4E Preliminary Final Report and to update the company's existing Registration Statements on Form S-8 and Form F-3.
What is the reporting period for this Form 6-K?
The Form 6-K is for the month of August 2024.
Which specific registration statements are being updated by this filing?
This Form 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is the previous name of Alterity Therapeutics Ltd.?
The former company name was PRANA BIOTECHNOLOGY LTD, with a date of name change on January 5, 2001.
Where is Alterity Therapeutics Ltd. headquartered?
Alterity Therapeutics Ltd. has its principal executive office at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-08-29 06:07:27
Filing Documents
- ea0212784-6k_alterity.htm (6-K) — 13KB
- ea021278401ex99-1_alterity.htm (EX-99.1) — 218KB
- ex99-1_001.jpg (GRAPHIC) — 289KB
- 0001213900-24-073515.txt ( ) — 630KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Appendix 4E Preliminary Final Report - ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: August 29, 2024 2